Khang & Khang LLP announces that it is investigating claims of potential
misrepresentations by Esperion Therapeutics, Inc. (“Esperion” or the
“Company”) (NASDAQ: ESPR).
The investigation focuses on whether the Company and its officers
violated securities laws by issuing misleading information to investors.
If you purchased shares of Esperion during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: 949-419-3834, or by
e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
The investigation concerns whether the Company violated Sections 10(b)
and 20(a) of the Securities Exchange Act of 1934. Specifically, the
investigation will focus on whether the Company’s efforts to receive
regulatory approval for its developmental cholesterol drug, ETC-1002,
was in accordance with the law.
If you wish to learn more about this lawsuit, or if you have any
questions concerning this notice or your rights, please contact Joon M.
Khang, a prominent litigator for almost two decades, by telephone:
949-419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106006793/en/
Copyright Business Wire 2016